US EditionIDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA projects topline progression-free survival results in Q1 2026 from its darovasertib trial, aiming for potential accelerated US approval and advancing multiple registrational studies.
- On Monday, January 12, 2026, IDEAYA Biosciences, Inc. presented a business update and 2026 objectives at the 44th Annual J.P. Morgan Healthcare Conference after issuing a Jan. 11 press release from SOUTH SAN FRANCISCO, Calif.
- To highlight near-term catalysts, IDEAYA said darovasertib topline PFS results are expected in Q1 '26 and showcased its antibody-drug conjugates and synthetic lethality programs.
- The company detailed the OptimUM-02 mechanics, noting full enrollment of 437 patients and that the randomized PFS analysis will rely on the first 10 PFS events from an approximately 313 ITT patients randomized 2:1.
- If results are positive, IDEAYA said a topline PFS could enable a potential accelerated approval filing in the United States, with Yujiro S. Hata emphasizing the trials' focus on patients with uveal melanoma.
- Beyond darovasertib, IDEAYA plans a CDKN2A candidate to enable combinations with IDE892, IDE397, and IDE574, supported by $1 billion in cash as of 9/30/25 to fund programs into 2030.
20 Articles
20 Articles
Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
SHANGHAI and BOSTON, Jan. 11, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief Executive Officer will…
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference - MBX Biosciences (NASDAQ:MBX)
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amy…
Helena Independent Record
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key corporate objectives for 2026. The company will review these updates during…
Presentation to J.P. Morgan Healthcare Conference
Presentation to J.P. Morgan Healthcare Conference Melbourne (Australia) and Indianapolis (United States) | 12 January 2026 Telix is pleased to provide a copy of the presentation that will be delivered by Dr. Christian Behrenbruch, Managing Director and Group CEO at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.). The presentation takes place on Monday, 12 January at 9:00 am PST (12:00 pm EST / 4:00 am …
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
